» Articles » PMID: 25698928

Systems Biology Analysis of the Proteomic Alterations Induced by MPP(+), a Parkinson's Disease-related Mitochondrial Toxin

Overview
Specialty Cell Biology
Date 2015 Feb 21
PMID 25698928
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a complex neurodegenerative disease whose etiology has not been completely characterized. Many cellular processes have been proposed to play a role in the neuronal damage and loss: defects in the proteosomal activity, altered protein processing, increased reactive oxygen species burden. Among them, the involvement of a decreased activity and an altered disposal of mitochondria is becoming more and more evident. The mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)), an inhibitor of complex I, has been widely used to reproduce biochemical alterations linked to PD in vitro and its precursor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP), to induce a Parkinson-like syndrome in vivo. Therefore, we performed a meta-analysis of the literature of all the proteomic investigations of neuronal alterations due to MPP(+) treatment and compared it with our results obtained with a mitochondrial proteomic analysis of SH-SY5Y cells treated with MPP(+). By using open-source bioinformatics tools, we identified the biochemical pathways and the molecular functions mostly affected by MPP(+), i.e., ATP production, the mitochondrial unfolded stress response, apoptosis, autophagy, and, most importantly, the synapse funcionality. Eventually, we generated protein networks, based on physical or functional interactions, to highlight the relationships among the molecular actors involved. In particular, we identified the mitochondrial protein HSP60 as the central hub in the protein-protein interaction network. As a whole, this analysis clarified the cellular responses to MPP(+), the specific mitochondrial proteome alterations induced and how this toxic model can recapitulate some pathogenetic events of PD.

Citing Articles

Hypoxia Pathways in Parkinson's Disease: From Pathogenesis to Therapeutic Targets.

Gao Y, Zhang J, Tang T, Liu Z Int J Mol Sci. 2024; 25(19).

PMID: 39408813 PMC: 11477385. DOI: 10.3390/ijms251910484.


The Role of Rab Proteins in Mitophagy: Insights into Neurodegenerative Diseases.

Shafique A, Brughera M, Lualdi M, Alberio T Int J Mol Sci. 2023; 24(7).

PMID: 37047239 PMC: 10094445. DOI: 10.3390/ijms24076268.


Human Molecular Chaperone Hsp60 and Its Apical Domain Suppress Amyloid Fibril Formation of α-Synuclein.

Yamamoto H, Fukui N, Adachi M, Saiki E, Yamasaki A, Matsumura R Int J Mol Sci. 2019; 21(1).

PMID: 31861692 PMC: 6982183. DOI: 10.3390/ijms21010047.


GSK-3β Inhibitor Alsterpaullone Attenuates MPP-Induced Cell Damage in a c-Myc-Dependent Manner in SH-SY5Y Cells.

Wang J, Li Y, Gao L, Yan F, Gao G, Li L Front Cell Neurosci. 2018; 12:283.

PMID: 30233322 PMC: 6127625. DOI: 10.3389/fncel.2018.00283.


The delta-opioid receptor and Parkinson's disease.

Huang J, Ren Y, Xu Y, Chen T, Xia T, Li Z CNS Neurosci Ther. 2018; 24(12):1089-1099.

PMID: 30076686 PMC: 6489828. DOI: 10.1111/cns.13045.


References
1.
Winterhalter C, Widera P, Krasnogor N . JEPETTO: a Cytoscape plugin for gene set enrichment and topological analysis based on interaction networks. Bioinformatics. 2013; 30(7):1029-30. PMC: 3967109. DOI: 10.1093/bioinformatics/btt732. View

2.
Nakamura K, Bindokas V, Marks J, Wright D, Frim D, Miller R . The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol. 2000; 58(2):271-8. DOI: 10.1124/mol.58.2.271. View

3.
Liu B, Shi Q, Ma S, Feng N, Li J, Wang L . Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice. Biochem Biophys Res Commun. 2008; 376(2):277-82. DOI: 10.1016/j.bbrc.2008.08.142. View

4.
Geisler S, Holmstrom K, Skujat D, Fiesel F, Rothfuss O, Kahle P . PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010; 12(2):119-31. DOI: 10.1038/ncb2012. View

5.
Morais V, Verstreken P, Roethig A, Smet J, Snellinx A, Vanbrabant M . Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med. 2010; 1(2):99-111. PMC: 3378121. DOI: 10.1002/emmm.200900006. View